CompuMed, Inc.
CMPD · OTC
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 1.42 | -0.24 | 0.08 |
| FCF Yield | 7.43% | 3.04% | -2.58% | 3.88% |
| EV / EBITDA | 3.93 | 6.16 | 4.87 | 8.37 |
| Quality | ||||
| ROIC | 5.26% | -1.98% | 12.42% | 24.51% |
| Gross Margin | 48.61% | 49.44% | 51.90% | 52.95% |
| Cash Conversion Ratio | 4.55 | -15.96 | 1.47 | 1.33 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.76% | -2.60% | 6.51% | 7.76% |
| Free Cash Flow Growth | 136.53% | 186.63% | -132.24% | 97.99% |
| Safety | ||||
| Net Debt / EBITDA | -1.09 | -0.99 | -1.13 | -0.98 |
| Interest Coverage | 5.39 | -1.17 | 12.66 | 17.39 |
| Efficiency | ||||
| Inventory Turnover | 14.16 | 7.37 | 22.62 | 19.23 |
| Cash Conversion Cycle | 53.41 | 52.99 | 25.06 | 36.67 |